233 related articles for article (PubMed ID: 30864729)
1. PD‑L1 promotes head and neck squamous cell carcinoma cell growth through mTOR signaling.
Zheng A; Li F; Chen F; Zuo J; Wang L; Wang Y; Chen S; Xiao B; Tao Z
Oncol Rep; 2019 May; 41(5):2833-2843. PubMed ID: 30864729
[TBL] [Abstract][Full Text] [Related]
2. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
Shen YQ; Guerra-Librero A; Fernandez-Gil BI; Florido J; García-López S; Martinez-Ruiz L; Mendivil-Perez M; Soto-Mercado V; Acuña-Castroviejo D; Ortega-Arellano H; Carriel V; Diaz-Casado ME; Reiter RJ; Rusanova I; Nieto A; López LC; Escames G
J Pineal Res; 2018 Apr; 64(3):. PubMed ID: 29247557
[TBL] [Abstract][Full Text] [Related]
3. Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma.
Chou MH; Chuang HC; Lin YT; Tsai MH; Kao YH; Lin IC; Huang TL; Fang FM; Chien CY
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802643
[TBL] [Abstract][Full Text] [Related]
4. A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.
Amornphimoltham P; Patel V; Leelahavanichkul K; Abraham RT; Gutkind JS
Cancer Res; 2008 Feb; 68(4):1144-53. PubMed ID: 18281490
[TBL] [Abstract][Full Text] [Related]
5. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
Xie J; Li Q; Ding X; Gao Y
Cell Physiol Biochem; 2018; 46(2):676-686. PubMed ID: 29621758
[TBL] [Abstract][Full Text] [Related]
6. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
7. Modulation of PD‑L1 expression by standard therapy in head and neck cancer cell lines and exosomes.
Affolter A; Liebel K; Tengler L; Seiz E; Tiedtke M; Azhakesan A; Schütz J; Theodoraki MN; Kern J; Ruder AM; Fleckenstein J; Weis CA; Bieback K; Kramer B; Lammert A; Scherl C; Rotter N; Ludwig S
Int J Oncol; 2023 Sep; 63(3):. PubMed ID: 37503786
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.
Day TA; Shirai K; O'Brien PE; Matheus MG; Godwin K; Sood AJ; Kompelli A; Vick JA; Martin D; Vitale-Cross L; Callejas-Varela JL; Wang Z; Wu X; Harismendy O; Molinolo AA; Lippman SM; Van Waes C; Szabo E; Gutkind JS
Clin Cancer Res; 2019 Feb; 25(4):1156-1164. PubMed ID: 30420444
[TBL] [Abstract][Full Text] [Related]
9. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
Coppock JD; Wieking BG; Molinolo AA; Gutkind JS; Miskimins WK; Lee JH
Neoplasia; 2013 Jun; 15(6):620-30. PubMed ID: 23730210
[TBL] [Abstract][Full Text] [Related]
10. Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma.
Zhang L; Zhang W; Wang YF; Liu B; Zhang WF; Zhao YF; Kulkarni AB; Sun ZJ
Cell Death Dis; 2015 May; 6(5):e1771. PubMed ID: 26018732
[TBL] [Abstract][Full Text] [Related]
11. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro.
Li Q; Song XM; Ji YY; Jiang H; Xu LG
Biochem Biophys Res Commun; 2013 Nov; 440(4):701-6. PubMed ID: 24103749
[TBL] [Abstract][Full Text] [Related]
12. MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in gastric cancer cells.
Tong G; Cheng B; Li J; Wu X; Nong Q; He L; Li X; Li L; Wang S
Cancer Med; 2019 Nov; 8(16):7044-7054. PubMed ID: 31557409
[TBL] [Abstract][Full Text] [Related]
13. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
Sun ZJ; Zhang L; Hall B; Bian Y; Gutkind JS; Kulkarni AB
Clin Cancer Res; 2012 Oct; 18(19):5304-13. PubMed ID: 22859719
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase D3 regulates the expression of the immunosuppressive protein, PD‑L1, through STAT1/STAT3 signaling.
Cui B; Chen J; Luo M; Wang L; Chen H; Kang Y; Wang J; Zhou X; Feng Y; Zhang P
Int J Oncol; 2020 Apr; 56(4):909-920. PubMed ID: 32319563
[TBL] [Abstract][Full Text] [Related]
15. Curcumin inhibits carcinogen and nicotine-induced Mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma.
Clark CA; McEachern MD; Shah SH; Rong Y; Rong X; Smelley CL; Caldito GC; Abreo FW; Nathan CO
Cancer Prev Res (Phila); 2010 Dec; 3(12):1586-95. PubMed ID: 20851953
[TBL] [Abstract][Full Text] [Related]
16. Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.
Madera D; Vitale-Cross L; Martin D; Schneider A; Molinolo AA; Gangane N; Carey TE; McHugh JB; Komarck CM; Walline HM; William WN; Seethala RR; Ferris RL; Gutkind JS
Cancer Prev Res (Phila); 2015 Mar; 8(3):197-207. PubMed ID: 25681087
[TBL] [Abstract][Full Text] [Related]
17. mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.
Coppock JD; Vermeer PD; Vermeer DW; Lee KM; Miskimins WK; Spanos WC; Lee JH
Oncotarget; 2016 Apr; 7(17):24228-41. PubMed ID: 27015118
[TBL] [Abstract][Full Text] [Related]
18. PDK1 Mediates
Sambandam V; Frederick MJ; Shen L; Tong P; Rao X; Peng S; Singh R; Mazumdar T; Huang C; Li Q; Pickering CR; Myers JN; Wang J; Johnson FM
Clin Cancer Res; 2019 Jun; 25(11):3329-3340. PubMed ID: 30770351
[TBL] [Abstract][Full Text] [Related]
19. A novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma.
Ma H; Chang H; Yang W; Lu Y; Hu J; Jin S
Mol Cancer; 2020 Jan; 19(1):4. PubMed ID: 31907020
[TBL] [Abstract][Full Text] [Related]
20. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
Ku BM; Yi SY; Koh J; Bae YH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Oncotarget; 2016 Mar; 7(12):14803-13. PubMed ID: 26909611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
